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Between 2012 and 2014, the Democratic Republic of Congo has gradually implemented 22 GeneXpert machines. The 
overall proportion of non-valid results (i.e. « error », « invalid » and « no result ») was 8%. Among the 68 analytical modules 
composing the 22 GeneXpert, 32% presented a significantly higher rate of non-valid results during the first 3 years of 
implementation, leading to unnecessary work and consumption of reagents as well as loss of diagnostic opportunities. The 
objective of this study was to determine whether it was possible to early identify modules presenting sub-optimal 
performance.  
Data was collected from 8 GeneXpert (34 
modules) located in the South-Kivu Province 
using the GenXchange (UCLouvain, Belgium; 
NTP, DRC) and XpertSMS (IRD, Pakistan) 
technology. We separated the modules in two 
groups: 11 modules identified with a high 
proportion of non-valid results, and 23 
modules presenting normal figures. Figure 1 
represents the activity  (diameter of circles) 
and error rate (grayscale) for all  GeneXpert 
analytical modules. Modules presenting an 
error rate superior to 10% are circled in red). 
Figure 2 represent the percentage of non-valid 
results between the two groups of modules.  In the 
group with a higher rate of non-valid results, all 
showed signs of dysfunction (proportion of not-
valid results higher than 10%) from the first month 
after implementation. This separation between the 
two groups increased with the time, and was 
maximal after 6 months of activity. 
It had been previously reported that 32% of GeneXpert MTB/Rif modules presented signs of 
dysfunction during the first three years after implementation. We showed that failing modules 
present early signs of dysfunction which can be  
identified as early as the first month after implementation by using adequate automatic reporting 
systems.   We conclude that the one-year free-of-charge warranty from the manufacturer will 
cover the vast majority of costs related to sub-optimal equipment delivered. Nevertheless, as 
failing modules can be difficult to identify, it is recommended to implement the adequate 
surveillance solutions in order to maximize the benefit that can be made from this warranty.  
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This first figure further shows that the main cause of invalid tests is linked with analytical modules rather than linked with 
other issues (GeneXpert instrument or local environment). 
 
For each group of modules, we computed the proportion of non-valid results based on time after implementation of the 
GeneXpert. We used a moving average on 30 days. 
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